{"id":68641,"date":"2026-06-22T14:33:37","date_gmt":"2026-06-22T06:33:37","guid":{"rendered":"https:\/\/flcube.com\/?p=68641"},"modified":"2026-06-22T14:33:38","modified_gmt":"2026-06-22T06:33:38","slug":"samsung-biologics-and-organon-expand-biosimilars-partnership-with-canadian-rights-for-pyzchiva-ustekinumab","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68641","title":{"rendered":"Samsung Biologics and Organon Expand Biosimilars Partnership with Canadian Rights for Pyzchiva (Ustekinumab)"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Samsung Biologics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/207940:KRX\">KRX: 207940<\/a>) and <strong>Organon<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/OGN:NYSE\">NYSE: OGN<\/a>) announced an expansion of their strategic biosimilars collaboration, granting <strong>Organon commercialization rights<\/strong> for <strong>Pyzchiva<\/strong> (ustekinumab biosimilar) in the <strong>Canadian market<\/strong>, with a planned launch in <strong>2026<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-partnership-expansion-details\" class=\"wp-block-heading\">Partnership Expansion Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Samsung Biologics (CDMO) + Organon (Commercial partner)<\/td><\/tr><tr><td><strong>New Product<\/strong><\/td><td>Pyzchiva (ustekinumab biosimilar)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Canada<\/td><\/tr><tr><td><strong>Commercial Rights<\/strong><\/td><td>Exclusive to Organon<\/td><\/tr><tr><td><strong>Expected Launch<\/strong><\/td><td>2026<\/td><\/tr><tr><td><strong>Existing Portfolio<\/strong><\/td><td>5 biosimilars across multiple therapeutic areas<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-existing-biosimilars-portfolio\" class=\"wp-block-heading\">Existing Biosimilars Portfolio<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The expanded agreement builds upon Samsung Biologics&#8217; established partnership with Organon, which already includes five marketed biosimilars:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hadlima<\/strong> (adalimumab) \u2013 TNF inhibitor for autoimmune diseases<\/li>\n\n\n\n<li><strong>Brenzys<\/strong> (etanercept) \u2013 TNF inhibitor for rheumatoid arthritis and psoriasis<\/li>\n\n\n\n<li><strong>Renflexis<\/strong> (infliximab) \u2013 TNF inhibitor for inflammatory conditions<\/li>\n\n\n\n<li><strong>Aybintio<\/strong> (bevacizumab) \u2013 Anti-angiogenic for oncology indications<\/li>\n\n\n\n<li><strong>Ontruzant<\/strong> (trastuzumab) \u2013 HER2-targeted therapy for breast cancer<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The addition of <strong>Pyzchiva<\/strong> (ustekinumab biosimilar) represents the sixth product in the collaboration, targeting the <strong>IL-12\/23 pathway<\/strong> for psoriasis, psoriatic arthritis, and Crohn&#8217;s disease.<\/p>\n\n\n\n<h2 id=\"h-strategic-rationale\" class=\"wp-block-heading\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Opportunity:<\/strong> The Canadian biosimilars market is projected to reach <strong>CAD $1.2 billion by 2027<\/strong>, with ustekinumab representing a high-value target due to its premium pricing and patent expiry timeline.<\/li>\n\n\n\n<li><strong>Organon&#8217;s Commercial Infrastructure:<\/strong> Leveraging Organon&#8217;s established presence in Canada&#8217;s women&#8217;s health and biosimilars markets to accelerate Pyzchiva adoption.<\/li>\n\n\n\n<li><strong>Samsung Biologics&#8217; Manufacturing Scale:<\/strong> Utilizing Samsung&#8217;s world-class CDMO capabilities, including its 256,000L bioreactor capacity, to ensure reliable supply.<\/li>\n\n\n\n<li><strong>Portfolio Diversification:<\/strong> Expanding beyond TNF inhibitors into the IL-12\/23 pathway strengthens the partnership&#8217;s therapeutic area coverage.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape\" class=\"wp-block-heading\">Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ustekinumab Market:<\/strong> Original product Stelara generated <strong>US$7.4 billion globally in 2025<\/strong>, with Canadian sales estimated at <strong>CAD $280 million<\/strong>.<\/li>\n\n\n\n<li><strong>Biosimilar Competition:<\/strong> Pyzchiva will compete with other ustekinumab biosimilars from Alvotech, Fresenius Kabi, and Celltrion, but benefits from Samsung Biologics&#8217; manufacturing expertise and Organon&#8217;s commercial experience.<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Health Canada&#8217;s progressive biosimilars approval framework supports rapid market entry following successful comparability studies.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-financial-implications\" class=\"wp-block-heading\">Financial Implications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">While specific financial terms were not disclosed, industry analysts estimate the Canadian ustekinumab biosimilar market could generate <strong>CAD $150-200 million annually<\/strong> by 2028, with Organon capturing 25-30% market share based on its existing biosimilars performance.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding product launches, market opportunities, and partnership outcomes. Actual results may differ due to regulatory approvals, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Samsung Biologics (KRX: 207940) and Organon (NYSE: OGN) announced an expansion of their strategic biosimilars&#8230;<\/p>\n","protected":false},"author":1,"featured_media":68642,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[1],"tags":[2218,972,174,2217],"class_list":["post-68641","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-krx-207940","tag-nyse-ogn","tag-organon","tag-samsung-biologics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Samsung Biologics and Organon Expand Biosimilars Partnership with Canadian Rights for Pyzchiva (Ustekinumab) - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Samsung Biologics (KRX: 207940) and Organon (NYSE: OGN) announced an expansion of their strategic biosimilars collaboration, granting Organon commercialization rights for Pyzchiva (ustekinumab biosimilar) in the Canadian market, with a planned launch in 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68641\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Samsung Biologics and Organon Expand Biosimilars Partnership with Canadian Rights for Pyzchiva (Ustekinumab)\" \/>\n<meta property=\"og:description\" content=\"Samsung Biologics (KRX: 207940) and Organon (NYSE: OGN) announced an expansion of their strategic biosimilars collaboration, granting Organon commercialization rights for Pyzchiva (ustekinumab biosimilar) in the Canadian market, with a planned launch in 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68641\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-22T06:33:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-22T06:33:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2203.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68641#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68641\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Samsung Biologics and Organon Expand Biosimilars Partnership with Canadian Rights for Pyzchiva (Ustekinumab)\",\"datePublished\":\"2026-06-22T06:33:37+00:00\",\"dateModified\":\"2026-06-22T06:33:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68641\"},\"wordCount\":380,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68641#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2203.webp\",\"keywords\":[\"KRX: 207940\",\"NYSE: OGN\",\"Organon\",\"Samsung Biologics\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68641#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68641\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68641\",\"name\":\"Samsung Biologics and Organon Expand Biosimilars Partnership with Canadian Rights for Pyzchiva (Ustekinumab) - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68641#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68641#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2203.webp\",\"datePublished\":\"2026-06-22T06:33:37+00:00\",\"dateModified\":\"2026-06-22T06:33:38+00:00\",\"description\":\"Samsung Biologics (KRX: 207940) and Organon (NYSE: OGN) announced an expansion of their strategic biosimilars collaboration, granting Organon commercialization rights for Pyzchiva (ustekinumab biosimilar) in the Canadian market, with a planned launch in 2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68641#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68641\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68641#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2203.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2203.webp\",\"width\":1080,\"height\":608,\"caption\":\"Samsung Biologics and Organon Expand Biosimilars Partnership with Canadian Rights for Pyzchiva (Ustekinumab)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68641#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Samsung Biologics and Organon Expand Biosimilars Partnership with Canadian Rights for Pyzchiva (Ustekinumab)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Samsung Biologics and Organon Expand Biosimilars Partnership with Canadian Rights for Pyzchiva (Ustekinumab) - Insight, China&#039;s Pharmaceutical Industry","description":"Samsung Biologics (KRX: 207940) and Organon (NYSE: OGN) announced an expansion of their strategic biosimilars collaboration, granting Organon commercialization rights for Pyzchiva (ustekinumab biosimilar) in the Canadian market, with a planned launch in 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68641","og_locale":"en_US","og_type":"article","og_title":"Samsung Biologics and Organon Expand Biosimilars Partnership with Canadian Rights for Pyzchiva (Ustekinumab)","og_description":"Samsung Biologics (KRX: 207940) and Organon (NYSE: OGN) announced an expansion of their strategic biosimilars collaboration, granting Organon commercialization rights for Pyzchiva (ustekinumab biosimilar) in the Canadian market, with a planned launch in 2026.","og_url":"https:\/\/flcube.com\/?p=68641","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-22T06:33:37+00:00","article_modified_time":"2026-06-22T06:33:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2203.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68641#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68641"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Samsung Biologics and Organon Expand Biosimilars Partnership with Canadian Rights for Pyzchiva (Ustekinumab)","datePublished":"2026-06-22T06:33:37+00:00","dateModified":"2026-06-22T06:33:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68641"},"wordCount":380,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=68641#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2203.webp","keywords":["KRX: 207940","NYSE: OGN","Organon","Samsung Biologics"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68641#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68641","url":"https:\/\/flcube.com\/?p=68641","name":"Samsung Biologics and Organon Expand Biosimilars Partnership with Canadian Rights for Pyzchiva (Ustekinumab) - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=68641#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=68641#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2203.webp","datePublished":"2026-06-22T06:33:37+00:00","dateModified":"2026-06-22T06:33:38+00:00","description":"Samsung Biologics (KRX: 207940) and Organon (NYSE: OGN) announced an expansion of their strategic biosimilars collaboration, granting Organon commercialization rights for Pyzchiva (ustekinumab biosimilar) in the Canadian market, with a planned launch in 2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68641#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68641"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=68641#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2203.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2203.webp","width":1080,"height":608,"caption":"Samsung Biologics and Organon Expand Biosimilars Partnership with Canadian Rights for Pyzchiva (Ustekinumab)"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68641#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Samsung Biologics and Organon Expand Biosimilars Partnership with Canadian Rights for Pyzchiva (Ustekinumab)"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2203.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68641","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68641"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68641\/revisions"}],"predecessor-version":[{"id":68643,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68641\/revisions\/68643"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/68642"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68641"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68641"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}